Dementia specialists and PET imaging providers are now welcome to register for the $100 million Imaging Dementia -- Evidence for Amyloid Scanning (IDEAS) study.
The four-year research effort will investigate whether amyloid PET imaging can improve clinical decision-making and patient outcomes for Alzheimer's disease.
More than 200 PET imaging facilities are expected to contribute to the study. The U.S. Centers for Medicare and Medicaid Services (CMS) will reimburse participating facilities approximately $80 million for costs associated with the PET scans.
The IDEAS study is led by the Alzheimer's Association and managed by the American College of Radiology (ACR) and American College of Radiology Imaging Network (ACRIN). The Society of Nuclear Medicine and Molecular Imaging (SNMMI) was also instrumental in developing appropriate use criteria for amyloid PET scans.
Three companies currently manufacture and supply amyloid PET imaging agents to assess patients for dementia and Alzheimer's disease: Eli Lilly, with florbetapir (Amyvid); GE Healthcare, with flutemetamol F-18 injection (Vizamyl); and Piramal Imaging, with florbetaben F-18 (Neuraceq).
Registration is available at Ideas-Study.org.
